Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

Robert Chapman, Loretta Itri, Richard J. Gralla, David Kelsen, Ephraim Casper, Robert Golbey

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4′ demethylepipodophyllotoxin-β-d-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may have adversely affected response rate; none of the 24 previously treated patients had a major response. Myelosuppression was the dose limiting toxicity. Anorexia, nausea and vomiting, partial alopecia, and chills plus hypotension during drug infusion were the other toxic effects. We conclude that VP16-213 has only minimal activity as a single agent in NSCLC.

Original languageEnglish (US)
Pages (from-to)205-207
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume7
Issue number2-3
DOIs
StatePublished - 1982
Externally publishedYes

Fingerprint

Drug infusion
Chemotherapy
Poisons
Glucosides
Non-Small Cell Lung Carcinoma
Toxicity
Cells
Chills
Alopecia
Anorexia
Hypotension
Nausea
Vomiting
Drug Therapy
Pharmaceutical Preparations
4'-demethylepipodophyllotoxin
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Chapman, R., Itri, L., Gralla, R. J., Kelsen, D., Casper, E., & Golbey, R. (1982). Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology, 7(2-3), 205-207. https://doi.org/10.1007/BF00254550

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC). / Chapman, Robert; Itri, Loretta; Gralla, Richard J.; Kelsen, David; Casper, Ephraim; Golbey, Robert.

In: Cancer Chemotherapy and Pharmacology, Vol. 7, No. 2-3, 1982, p. 205-207.

Research output: Contribution to journalArticle

Chapman, R, Itri, L, Gralla, RJ, Kelsen, D, Casper, E & Golbey, R 1982, 'Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)', Cancer Chemotherapy and Pharmacology, vol. 7, no. 2-3, pp. 205-207. https://doi.org/10.1007/BF00254550
Chapman, Robert ; Itri, Loretta ; Gralla, Richard J. ; Kelsen, David ; Casper, Ephraim ; Golbey, Robert. / Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC). In: Cancer Chemotherapy and Pharmacology. 1982 ; Vol. 7, No. 2-3. pp. 205-207.
@article{12b7bfa2c8764a369d175eef546d0f74,
title = "Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)",
abstract = "Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4′ demethylepipodophyllotoxin-β-d-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4{\%}) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may have adversely affected response rate; none of the 24 previously treated patients had a major response. Myelosuppression was the dose limiting toxicity. Anorexia, nausea and vomiting, partial alopecia, and chills plus hypotension during drug infusion were the other toxic effects. We conclude that VP16-213 has only minimal activity as a single agent in NSCLC.",
author = "Robert Chapman and Loretta Itri and Gralla, {Richard J.} and David Kelsen and Ephraim Casper and Robert Golbey",
year = "1982",
doi = "10.1007/BF00254550",
language = "English (US)",
volume = "7",
pages = "205--207",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2-3",

}

TY - JOUR

T1 - Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

AU - Chapman, Robert

AU - Itri, Loretta

AU - Gralla, Richard J.

AU - Kelsen, David

AU - Casper, Ephraim

AU - Golbey, Robert

PY - 1982

Y1 - 1982

N2 - Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4′ demethylepipodophyllotoxin-β-d-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may have adversely affected response rate; none of the 24 previously treated patients had a major response. Myelosuppression was the dose limiting toxicity. Anorexia, nausea and vomiting, partial alopecia, and chills plus hypotension during drug infusion were the other toxic effects. We conclude that VP16-213 has only minimal activity as a single agent in NSCLC.

AB - Fifty-one patients with non-small cell lung cancer (NSCLC) were treated, during a phase II trial, with 4′ demethylepipodophyllotoxin-β-d-ethylidene glucoside (VP16-213). Forty-nine were evaluable for response, and of these two (4%) had partial responses lasting 5 and 6 months. Prior treatment with chemotherapy may have adversely affected response rate; none of the 24 previously treated patients had a major response. Myelosuppression was the dose limiting toxicity. Anorexia, nausea and vomiting, partial alopecia, and chills plus hypotension during drug infusion were the other toxic effects. We conclude that VP16-213 has only minimal activity as a single agent in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0020040619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020040619&partnerID=8YFLogxK

U2 - 10.1007/BF00254550

DO - 10.1007/BF00254550

M3 - Article

C2 - 7083460

AN - SCOPUS:0020040619

VL - 7

SP - 205

EP - 207

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2-3

ER -